---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-043664"
form_type: "8-K"
ticker: "MOVE"
cik: "0001734750"
company_name: "Corvex, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:23:23.302940+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Movano Health reports Q1 revenue $852k, operating loss $5.8M; closes $24M private placement

## Summary
- Q1 2024 revenue $852,000 from 5,305 Evie Rings shipped; operating loss $5.8M vs $7.2M a year ago.
- Closed $24.1M private placement on April 4, 2024, including investment from a tier-1 medical device company.
- FDA 510(k) decision for Evie Med Ring pulse oximeter expected July 2024; SpO2 trial RMSE 2.46% (below 3.5% FDA guidance).
- Planning arterial blood pressure study in June using arterial line for continuous data.
- Cash and cash equivalents $2.1M at March 31, 2024; D2C orders paused pending improvements.

## SEC filing metadata
- accession: 0001213900-24-043664
- form_type: 8-K
- ticker: MOVE
- cik: 0001734750
- company_name: Corvex, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734750/000121390024043664/0001213900-24-043664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734750/000121390024043664/ea0206242-8k_movano.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-043664
- JSON: https://secwatch.observer/filing/0001213900-24-043664.json
- Plain text: https://secwatch.observer/filing/0001213900-24-043664.txt

## Key facts
- Earnings Releases
  Corvex, Inc. reported the quarter ended March 31, 2024 results: revenue $852,000.
  - Period: the quarter ended March 31, 2024
  - Revenue: $852,000
  - Result: reported results
  source text: board of directors. Movano Health intends to use the net proceeds from the financing for working capital and general corporate purposes. ● In Q1 2024, Movano Health generated $852,000 in revenue. The Company shipped 5,305 Evie Rings in the period. ● The Company reported an operating loss of $5.8 million in Q1 2024, compared to an operating loss of $7.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1734750/000121390024043664/0001213900-24-043664-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.